Analyst Ratings For Mirum Pharmaceuticals
In the preceding three months, 10 analysts have released ratings for Mirum Pharmaceuticals (NASDAQ:MIRM), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 5 | 5 | 0 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 1 | 0 | 0 | 0 | 0 |
2M Ago | 2 | 2 | 0 | 0 | 0 |
3M Ago | 1 | 3 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $52.6, a high estimate of $72.00, and a low estimate of $35.00. This current average represents a 1.29% decrease from the previous average price target of $53.29.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive Mirum Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Ed Arce | HC Wainwright & Co. | Maintains | Buy | $58.00 | - |
Dae Gon Ha | Stifel | Announces | Buy | $48.00 | - |
Ed Arce | HC Wainwright & Co. | Maintains | Buy | $58.00 | $58.00 |
Mani Foroohar | Leerink Partners | Lowers | Outperform | $43.00 | $44.00 |
Jonathan Wolleben | JMP Securities | Raises | Outperform | $72.00 | $69.00 |
Ed Arce | HC Wainwright & Co. | Raises | Buy | $58.00 | $45.00 |
Josh Schimmer | Cantor Fitzgerald | Raises | Overweight | $40.00 | $35.00 |
Ed Arce | HC Wainwright & Co. | Lowers | Buy | $45.00 | $58.00 |
Jonathan Wolleben | JMP Securities | Raises | Market Outperform | $69.00 | $64.00 |
Josh Schimmer | Cantor Fitzgerald | Maintains | Overweight | $35.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to ...
Full story available on Benzinga.com